Technical analysis of BioVie Inc. (BIVI): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
Price Performance
| 1 month | +78.35% |
| 3 months | -2.27% |
| Year-to-date | +48.28% |
| 1 year | -5.49% |
| 3 years | -99.46% |
| 5 years | -99.77% |
52-Week Range
| 52-week High | $3.79 |
| 52-week Low | $0.82 |
| Avg Volume (90d) | 3.3M |
Technical Indicators
| SMA 50 | $1.71 |
| SMA 200 | $1.51 |
| Beta | 0.56 |
| 30-day Volatility (annualised) | 242.8% |
| Price vs SMA 50 | +0.4% |
| Price vs SMA 200 | +13.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.75 | |
| 2025-11 | $1.50 | -14.3% |
| 2025-12 | $1.16 | -22.7% |
| 2026-01 | $1.14 | -1.7% |
| 2026-02 | $1.38 | +21.1% |
| 2026-03 | $1.40 | +1.4% |
| 2026-04 | $1.65 | +17.9% |
| 2026-05 | $1.42 | -13.9% |
| 2026-06 | $1.94 | +36.6% |
| 2026-07 | $1.52 | -21.6% |
| 2026-08 | $2.28 | +50.0% |
| 2026-09 | $1.72 | -24.6% |
Price
| Price | $1.72 |
| Market Cap | $13M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.29 |
| EV / EBITDA | -0.31 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 3.59 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -21.39 |